Solutia Reports Third Quarter 20...(Ended Ended Ended ...)

Date:10/26/2009

Ended Ended Ended Ended September 30, February 29, September 30, September 30, (dollars in millions) 2009 2008 2008 2008 ---- ---- ---- ---- Net Income (Loss) Attributable to Solutia $(120) $1,454 $(53) $1,401 Plus: Income Tax Expense 15 214 17 231 Interest Expense 98 21 107 128 Depreciation and Amortization 78 11 64 75 (Income) Loss from Discontinued Operations, net of tax 169 (204) 52 (152) Events affecting comparability, pre-tax: Reorganization items - (1,433) - (1,433) Other items (see below) 17 (2) 65 63 Non-cash Stock Compensation Expense 13 - 6 6 Nylon Cost Overhang 1 (1) 2 1 --- --- --- --- Adjusted EBITDA from Continuing Operations $271 $60 $260 $320 --- --- --- --- Reconciliation of Income (Loss) from Continuing Operations to Income from Continuing Operations Attributable to Solutia before Events Affecting Comparability Successor Successor --------- --------- Three Months Three Months Ended Ended September 30, September 30, (dollars in millio
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009